{
  "objCls" : "Guideline",
  "@id" : "https://www.pharmgkb.org/data/guideline/PA166104997",
  "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
  "id" : "PA166104997",
  "name" : "CPIC Dosing Guideline for abacavir and HLA-B",
  "groups" : [ {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://www.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128752",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128752",
    "name" : "Absent",
    "annotations" : [ {
      "id" : 1445560529,
      "text" : "Low or reduced risk of abacavir hypersensitivity",
      "textHtml" : "<p>Low or reduced risk of abacavir hypersensitivity</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "src" : "guidelineTags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925"
      }
    }, {
      "id" : 1445560765,
      "text" : "Very low risk of hypersensitivity (~94% of patients) in the absence of *57:01 alleles (reported as \"negative\" on a genotyping test)",
      "textHtml" : "<p>Very low risk of hypersensitivity (~94% of patients) in the absence of *57:01 alleles (reported as \"negative\" on a genotyping test)</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "src" : "guidelineTags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927"
      }
    }, {
      "id" : 1445560530,
      "text" : "Use abacavir per standard dosing guidelines",
      "textHtml" : "<p>Use abacavir per standard dosing guidelines</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "src" : "guidelineTags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928"
      }
    } ],
    "genotypes" : [ "HLA-B:Other/Other" ],
    "strength" : {
      "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501930",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501930,
      "src" : "guidelineStrength",
      "term" : "Strong",
      "termId" : "guidelineStrength:981501930"
    }
  }, {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://www.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128753",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128753",
    "name" : "Present",
    "annotations" : [ {
      "id" : 1445561001,
      "text" : "Significantly increased risk of abacavir hypersensitivity",
      "textHtml" : "<p>Significantly increased risk of abacavir hypersensitivity</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "src" : "guidelineTags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925"
      }
    }, {
      "id" : 1445561000,
      "text" : "High risk of hypersensitivity (~6% of patients) due to the presence of at least one *57:01 allele (reported as \"positive\" on a genotyping test)",
      "textHtml" : "<p>High risk of hypersensitivity (~6% of patients) due to the presence of at least one *57:01 allele (reported as \"positive\" on a genotyping test)</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "src" : "guidelineTags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927"
      }
    }, {
      "id" : 1445561002,
      "text" : "Abacavir is not recommended",
      "textHtml" : "<p>Abacavir is not recommended</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "src" : "guidelineTags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928"
      }
    } ],
    "genotypes" : [ "HLA-B:*57:01:01/*57:01:01", "HLA-B:*57:01:01/Other" ],
    "strength" : {
      "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501930",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501930,
      "src" : "guidelineStrength",
      "term" : "Strong",
      "termId" : "guidelineStrength:981501930"
    }
  } ],
  "relatedChemicals" : [ {
    "objCls" : "Chemical",
    "@id" : "https://www.pharmgkb.org/data/chemical/PA448004",
    "@context" : "https://www.pharmgkb.org/jsonld/chemical.jsonld",
    "id" : "PA448004",
    "name" : "abacavir"
  } ],
  "relatedGenes" : [ {
    "objCls" : "Gene",
    "@id" : "https://www.pharmgkb.org/data/gene/PA35056",
    "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
    "id" : "PA35056",
    "symbol" : "HLA-B",
    "name" : "major histocompatibility complex, class I, B"
  } ],
  "source" : "CPIC",
  "summaryHtml" : "<p>In individuals with the HLA-B*57:01 variant allele (\"HLA-B*57:01-positive\"), abacavir is not recommended and should be considered only under exceptional circumstances. See full guideline for disclaimers, further details and supporting evidence.</p>",
  "textHtml" : "<h3 id=\"May2014\">May 2014</h3><p><em>Accepted article preview online 21 February 2014; Advance online publication 12 March 2014</em></p><p>The <a href=\"/redirect.jsp?p=http%3A%2F%2Fwww.nature.com%2Fclpt%2Fjournal%2Fv95%2Fn5%2Ffull%2Fclpt201438a.html\" target=\"offsite\">2014 update of CPIC guidelines</a> regarding abacavir has been published in <em>Clinical Pharmacology and Therapeutics</em>. Literature published between April 2011-November 2013 was reviewed and there is <strong>no new evidence that would change the original guidelines. Therefore, the dosing recommendations in the original publication remain clinically current</strong>. </p><ul><li>These guidelines are applicable to:<ul><li>HIV Patients</li></ul></li><li>Download and read:<ul><li><a href=\"/download.do?objCls=Attachment&amp;objId=CPIC_HLAB_Abacavir_Update.pdf\">Clinical Pharmacogenetics Implementation Consortium Guidelines for <em>HLA-B</em> Genotype and Abacavir Dosing: 2014 Update</a>.</li><li><a href=\"/download.do?objCls=Attachment&amp;objId=CPIC_Abacavir_HLAB_Supplement_Update_MA.pdf\">2014 supplement</a>.</li></ul></li></ul><h3 id=\"April2012\">April 2012</h3><p><em>Advance online publication February 2012</em></p><ul><li>Download and read:<ul><li><a href=\"/download.do?objCls=Attachment&amp;objId=CPIC_HLAB-Abacavir.pdf\">Clinical Pharmacogenetics Implementation Consortium Guidelines for <em>HLA-B</em> Genotype and Abacavir Dosing</a> </li><li><a href=\"/download.do?objCls=Attachment&amp;objId=CPIC_HLAB-Abacavir_Supplemental_Material.pdf\">2012 supplement</a>. </li></ul></li></ul><p>Excerpt from the abacavir dosing guidelines:</p><blockquote><p> We agree with others* that <em>HLA-B*57:01</em> screening should be performed in all abacavir-naive individuals before initiation of abacavir-containing therapy (see Table 1 below); this is consistent with the recommendations of the FDA, the US Department of Health and Human Services, and the European Medicines Agency. In abacavir-naive individuals who are <em>HLA-B*57:01</em>-positive, abacavir is not recommended and should be considered only under exceptional circumstances when the potential benefit, based on resistance patterns and treatment history, outweighs the risk. </p></blockquote><p>*[Articles:<a href=\"/pmid/18826546\">18826546</a>, <a href=\"/pmid/19640227\">19640227</a>, <a href=\"/pmid/21174626\">21174626</a>, <a href=\"/pmid/21412232\">21412232</a>] <a href=\"/redirect.jsp?p=http%3A%2F%2Fwww.aidsinfo.nih.gov%2FContentFiles%2FAdultandAdolescentGL.pdf\" target=\"offsite\">Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (PDF)</a></p><h3 id=\"Table1RecommendedtherapeuticuseofabacavirbasedonHLABgenotype\">Table 1: Recommended therapeutic use of abacavir based on <em>HLA-B</em> genotype</h3><p><em>Adapted from Tables 1 and 2 of the 2012 guideline manuscript.</em></p><table class=\"table table-striped table-condensed table-hover table-bordered\"><tr><th> Likely phenotype </th><th> Genotypes </th><th> Examples of diplotypes </th><th> Implications for phenotypic measures   </th><th> Recommendations for abacavir therapy </th><th> Classification of recommendation for abacavir therapy <sup>a</sup> </th></tr><tr><td>Very low risk of hypersensitivity (constitutes ~94% <sup>b</sup> of patients) </td><td> Absence of <em>*57:01</em> alleles (reported as \"negative\" on a genotyping test)</td><td> *X/*X <sup>c</sup></td><td>  Low or reduced risk of abacavir hypersensitivity  </td><td>  Use abacavir per standard dosing guidelines </td><td>  Strong </td></tr><tr><td>High risk of hypersensitivity (~6% of patients) </td><td> Presence of at least one <em>*57:01</em> allele (reported as \"positive\" on a genotyping test) </td><td> <em>*57:01</em>/*X <sup>c</sup> <em>*57:01/*57:01</em> </td><td> Significantly increased risk of abacavir hypersensitivity</td><td> Abacavir is not recommended </td><td>  Strong </td></tr></table><p><sup>a</sup> Rating scheme described in the <a href=\"/download.do?objCls=Attachment&amp;objId=CPIC_HLAB-Abacavir_Supplemental_Material.pdf\">2012 Supplement</a></p><p><sup>b</sup> See the <a href=\"/download.do?objCls=Attachment&amp;objId=CPIC_HLAB-Abacavir_Supplemental_Material.pdf\">2012 Supplement</a> for estimates of genotype frequencies among different ethnic/geographic groups</p><p><sup>c</sup> *X = any <em>HLA-B</em> genotype other than <em>*57:01</em>.<br/><em>HLA-B</em> = human leukocyte antigen B</p><p><strong>Listen to an interview with the lead author:</strong> <a href=\"/redirect.jsp?p=http%3A%2F%2Fwww.theaidsreader.com%2Fdisplay%2Farticle%2F1145619%2F2064707\" target=\"offsite\">podcast</a></p>"
}